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Abstract  
 CC chemokine Ligand 5 (CCL5) and CCL3 are critical for immune surveillance and 
inflammation. Consequently, they are linked to the pathogenesis of many inflammatory 
conditions and are therapeutic targets. Oligomerization and glycosaminoglycan (GAG)-binding 
of CCL5 and CCL3 are vital for the functions of these chemokines. Our structural and 
biophysical analyses of human CCL5 reveal that CCL5 oligomerization is a polymerization 
process in which CCL5 forms rod-shaped, double helical oligomers. This CCL5 structure 
explains mutational data and offers a unified mechanism for CCL3, CCL4, and CCL5 assembly 
into high molecular weight, polydisperse oligomers. A conserved, positively charged BBXB 
motif is key for the binding of CC chemokines to GAG. However, this motif is partially buried 
when CCL3, CCL4, and CCL5 are oligomerized; thus, the mechanism by which GAG binds 
these chemokine oligomers has been elusive. Our structures of GAG-bound CCL5 and CCL3 
oligomers reveal that these chemokine oligomers have distinct GAG-binding mechanisms. The 
CCL5 oligomer utilizes another positively charged and fully exposed motif, KKWVR, in GAG-
binding. However, residues from two partially buried BBXB motifs along with other residues 
combine to form a GAG-binding groove in the CCL3 oligomer. The N-termini of CC 
chemokines are shown to be involved in receptor binding and oligomerization. We also report 
an alternative CCL3 oligomer structure which reveals how conformational changes in CCL3 N-
termini profoundly alter its surface properties and dimer-dimer interactions to affect GAG 
binding and oligomerization. Such complexity in oligomerization and GAG binding enables 
intricate, physiologically relevant regulation of CC chemokine functions. 
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Significance 
 Oligomerization and GAG binding are key regulatory steps for many extracellular 
ligands. Our analyses provide a structural basis of CCL5 and CCL3 oligomerization and 
explain how oligomerization affects the interaction of these chemokines with GAG and their 
functions. Our GAG-bound chemokine structures reveal how CCL5 and CCL3 oligomerization 
creates distinctive GAG-binding grooves to enhance GAG binding via avidity for regulating 
chemokine functions. Furthermore, our CCL5 structure may explain how CXCL4, a CXC 
chemokine, heterooligomerizes with CCL5 to modulate chemokine-mediated activities. 
Together, these data provide new structural insights into how oligomerization and GAG binding 
are coupled to regulate functions of CC chemokines and offer novel pharmacophores for the 
design of therapeutics for treating chemokine-mediated human diseases.  
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\body 
Introduction 
 CC chemokines are a 28-member family of 8-14 kDa small molecular weight (MW) 
chemotactic cytokines with crucial roles in inflammation and infection (1, 2). Chemokine 
oligomerization and their interaction with glycosaminoglycans (GAGs), polysaccharides that 
are either free or attached to proteoglycans mostly on cell surface or in the extracellular matrix, 
is a coupled process that play key roles in chemokine functions (3-8). These include, but are 
not limited to, protection from proteolysis, regulation of chemotactic/haptatactic gradients to 
guide cell migration, transcytosis of chemokines across cells, and presentation to surface 
receptors of target cells, particularly under flow conditions. Most CC chemokines readily 
dimerize by themselves, and form higher MW complexes in the presence of GAGs (4). CCL3 
(MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) are CCR5 ligands that are involved in diverse 
proinflammatory responses and are targeted for therapeutic innovations for human diseases 
including cancer, cardiovascular diseases, and HIV infection (9-12). Unlike other CC 
chemokines, these chemokines reversibly self-assemble into high MW oligomers, up to >600 
kDa in size (13, 14). The presence of GAGs further modulates the oligomerization of these 
chemokines. Mutants of these chemokines with reduced oligomerization have chemotactic 
activity comparable to wild type chemokines (15, 16). However, such mutants make CCL3, 
CCL4, and CCL5 less effective at recruiting cells into the mouse peritoneum (14, 17, 18). 
CCL5 mutants defective in oligomerization fail to block HIV infection and induce the expression 
of interferon-γ and CCL4 (15, 19). Normally, CCL5 can trigger CCR5-dependent apoptosis and 
GPCR-independent MAP kinase activation via CD44, but CCL5 mutants defective in either 
oligomerization or GAG binding fail to elicit these responses (20, 21). Manipulation of CCL3 
oligomerization by mutation has led to the development of CCL3-based cancer therapies that 
preserve stem cells and boost immune therapy (11, 12, 22).  
Accumulating evidence indicates that oligomerization of CC chemokines occurs in vivo. 
For example, CCL5 is released from T cells as high MW, GAG-bound complexes (23) and 
filamentous CCL5 oligomers are found on vascular endothelial cells in a GAG-dependent 
manner (24). However, significant gaps exist in our understanding of the structural basis of CC 
chemokine oligomerization and GAG binding. While CCL3, CCL4, and CCL5 oligomerize 
readily under physiological conditions, only CCL3 and CCL4 oligomer structures are available 
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at a neutral pH (14) (Table S1). All available CCL5 structures were determined at acidic pH 
(25-30) (Table S1). Unfortunately, none explain how CCL5 mutations profoundly affect CCL5 
oligomerization and alter its biological functions (15, 16, 18-21, 31). Thus, the structural basis 
for CCL5 oligomerization is unknown. 
Significant efforts have been made to elucidate the structural basis of GAG binding to 
target proteins (3, 32, 33). Such efforts reveal the structural diversity of GAGs, their target 
proteins, and the interaction interfaces between them. Mutational and structural studies have 
confirmed a role of the BBXB motif (basic/basic/x/basic residue) in CC chemokines in GAG 
binding, oligomerization, and receptor binding (4, 5, 14, 28, 34). Structures of CCL3 and CCL4 
oligomers, however, show that the BBXB motif is located at the interface between dimers of 
these chemokines (14). Thus, oligomerization prevents the BBXB motif from binding GAG in 
the manner shown in the CCL5-GAG disaccharide structure (28). Thus, how GAG binds CC 
chemokine oligomers and how chemokine oligomerization affects GAG binding remains 
unknown. Here, we combined crystallographic, SAXS, and mathematical modeling analyses to 
unveil the structural basis for CCL5 oligomerization at a physiological pH. We also solved the 
structures of CCL3 and CCL5 oligomers in complex with synthetic heparin to elucidate the 
molecular basis for the interaction of CC chemokine oligomers with GAG.  
Results  
Structural basis of CCL5 oligomerization: To address the structural basis for CCL5 
oligomerization, we sought to identify a crystallization condition for CCL5 at neutral pH (Table 
S2). We found that the naturally occurring CCL5(4-68) variant of CCL5, in which three CCL5 
N-terminal residues are deleted, displays dramatically reduced CCL5 precipitation without 
affecting formation of high MW oligomers. While CCL5(4-68) could be crystalized at an acidic 
pH, it also formed crystals at a pH of 7.0-8.0 that was temperature sensitive (optimal at 30oC). 
Heparins, a well-known class of GAGs, have disaccharide repeats of glucosamine-iduronic 
acid or glucosamine-glucuronic acid that have 48 possible combinations (33). 23 of 48 possible 
repeats have been found in vivo. To determine a GAG-bound CCL5 oligomer structure, we 
used synthetic heparins that have one to four N,O6-disulfoglucosamine (SGN) and O2-
sulfoiduronic acid (IDS) repeats (Figure S1A) (33, 35, 36). The use of synthetic heparin 
eliminated the complexity and chemical heterogeneity of commercially available GAGs and 
allowed the formation of better diffracting crystals that had interpretable GAG density.  We first 
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solved the dimeric CCL5(4-68) structure crystallized at an acidic pH at 1.4Å resolution, then 
used it as a search model for molecular replacement. In conjunction with sulfur phasing, we 
solved the structure of CCL5(4-68) oligomer crystallized at a neutral pH in the presence and 
absence of heparin 8f, a synthetic heparin octasaccharide (Figure S1A) at 2.55Å and 3.05Å 
resolution, respectively (Table S2). The week-long dehydration of CCL5(4-68) crystals in the 
presence of 8f significantly improved diffraction quality. 
 The electron density of CCL5 is generally excellent except for the 4-10 N-terminal loop 
(Figure S1B). The structure of heparin-free CCL5(4-68) is a hexamer in an asymmetric unit 
(Figure 1A), while that of heparin 8f-bound CCL5(4-68) has nine monomers arranged as one 
and a half hexamers (Figure S1C). These hexameric structures are nearly identical (Figure 
S1D). The CCL5 hexamer can be viewed as a complex of three CCL5 dimers. Within the 
hexamer, the CCL5 monomer has an expected structure: a N-terminal segment (aa 4-20) 
followed by a 310 helical turn (aa 21-23), an anti-parallel three-stranded β-sheet (aa 24-55), and 
an α-helix (aa 55-68). The arrangement of CCL5 dimers is similar to dimeric CCL5 structures 
crystallized at low pH (Figure S1E-F) (25-30). However, the contacts between CCL5 dimers in 
our CCL5 oligomeric structure nicely explain how mutations affect CCL5 oligomerization and 
function. Between CCL5 dimers, E26 forms a salt bridge with R47 while E66 forms hydrogen 
bonds with T43 and R44 as well as a salt bridge with K45 (Figure 1B). This explains how the 
mutation of E66 or E26 to serine or alanine profoundly reduces CCL5 oligomerization and 
decreases its functionality while mutations at the 44RKNR47 BBXB motif also affect CCL5 
oligomerization (Figure S1G) (15, 16, 18-21). This structure also explains how the A22K 
mutation enhances CCL5 oligomerization, since this lysine would form a hydrogen bond to 
N63 of the adjacent CCL5 monomer (Figure S1H) (31). This structure can explain how an 
H23K mutation reduces CCL5 oligomerization by disrupting van der Waals contacts between 
H23 and N63 of the two CCL5 monomers (31).  
 The mechanism for forming double helical CCL5 oligomers is similar to that of 
CCL3 and CCL4 oligomers: The structure of CCL5(4-68) hexamer suggests that, like CCL3 
and CCL4, charge and surface complementarity allow CCL5 dimers to come together and 
polymerize into rod-shaped double helical oligomers that are polydisperse in size (Figure 1C-
D) (14). Residues that form hydrophilic interactions at the dimer-dimer interfaces are highly 
conserved between CCL3, CCL4 and CCL5, but not other CC chemokines (Figure 1E, S1I-J). 
This can explain why only these chemokines self-assemble into high MW oligomers. To probe 
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whether wild type CCL5 forms rod-shaped oligomers in solution, we performed SAXS analysis 
of CCL5 (0.5-1 mg/mL) in buffer containing Tris-HCl (pH=8) and 500 mM NaCl to prevent 
CCL5 from precipitating (Figure 2A). If CCL5 oligomers were rod-shaped, the linearity over a 
range of scattering vectors in the plot of cross-section, Guinier rod would be expected. Indeed, 
the observed plot revealed linearity at q values ranging from 0.03 to 0.09 (Figure 2A inset).  
 There are three available CCL5 oligomeric structures: a double helical rod based on our 
CCL5(4-68) structure (PDB=5CMD), a CCL5 structure derived from a hybrid method using 
NMR, SAXS and molecular simulation (PDB=2L9H), and P2-RANTES, which has enhanced 
the ability of CCL5 to inhibit HIV-1 infection due to its mutated N-terminal sequences 
(PDE=2VXW) (27, 29). All of them are rod-shaped. We first generated a oligomer model from 
each of the three structures that best fit the experimental Rg values and had χ values near 1 
(Figure 2A). We then evaluated which model best fit the experimental cross-section Rg value 
(Rc). We found that only the double helical CCL5 26mer derived from our CCL5(4-68) model fit 
the experimental scattering curves and Rc value well (Figure 2A). While the CCL5 26mer 
offered the best fit among the three models, the predicted maximal dimension (Dmax) of the 
CCL5 26mer (250 Å) deviated significantly from the observed Dmax value of CCL5 (350 Å, 
Figure 2A). We rationalize that CCL5 follows a simple polymerization mechanism, and thus 
should exist as an equilibrium mixture of monomers, dimers, and oligomers of different lengths 
(14, 37). Indeed, this model generated a pair distribution profile that fit well with the observed 
P(r) distribution (Figure 2A). Together with existing mutational studies (15, 16, 18-21), we 
conclude that our double helical CCL5 oligomer model represents how CCL5 forms 
polydisperse oligomers in solution under physiological conditions (Figure S1G). This could also 
represent CCL5 filaments found on the surface of endothelial cells that are polydisperse in size 
(24).  
 Under the same experimental conditions, we found that CCL3 had a much smaller Rg 
(38Å) than wild type CCL5 (88Å) (Figure 2B). We speculate that the additional hydrophobic 
contacts in CCL5 could render CCL5 more prone to form high MW oligomers than CCL3 
(Figure 1E). The Rg value of CCL3 was also much smaller than that of CCL3 observed in 
phosphate buffered saline (pH 7.2), which had an Rg value of 130 Å (14). This is likely because 
we used the higher NaCl concentration and slightly alkaline pH that could reduce the overall 
size of CCL3 oligomers. However, CCL3 retained its rod-shaped, polydisperse oligomeric 
structure (Figure 2B). We also performed a SAXS analysis of CCL5(4-68) under the same 
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condition. However, the SAXS profile of CCL5(4-68) revealed significant aggregation, which 
precludes meaningful interpretation (Figure S2B).  
Structure of heparin 8f-bound CCL5 and CCL3 oligomers: To address how GAG binds 
CCL5 oligomers, we solved a heparin 8f-bound CCL5 hexamer structure. Anomalous signals 
confirmed the position of sulfate atoms in heparin 8f (Figure S3A-B). For each CCL5(4-68) 
hexamer, two heparin 8f chains that contained three sugar moieties were clearly visible (Figure 
3A). The trisaccharide of 8f binds a positively charged groove involving R17, K55, K56 and 
R59 of the CCL5(4-68) oligomer (Figure 3B). In addition to hydrogen bonds and van der Waals 
contacts, K55, K56 and R59 form a network of salt bridges with the sulfate groups of SGN-I, 
IDS-II, and SGN-III (Figure 3C, 3D). Thus, heparin primarily binds the 55KKWVR59 motif of the 
CCL5 oligomer. This is consistent with the role of positively charged residue in the 55KKWVR59 
motif for GAG binding and biological functions, e.g. the adhesion of T lymphocytes and 
monocytes as well as leukocyte recruitment into the mouse peritoneal cavity (38). Previous 
analyses reveal that the 44RKNR47 BBXB motif is known to be crucial for GAG binding and a 
structure to elucidate how heparin disaccharide binds this motif has been determined (18, 28, 
34, 39). This BBXB motif, however, is largely buried in our CCL5 oligomer structure, which 
prevents it from binding heparin (Figure 3E, S3C). Thus, our structure indicates that the 
55KKWVR59 motif serves as the primary site to bind GAG when CCL5 is oligomerized. Our 
GAG-bound CCL5 structure suggested that the presence of heparin should significantly 
increase the propensity of CCL5 and CCL5(4-68) to form high MW aggregates. We probed the 
effect of heparin on CCL5 oligomerization by SAXS and found this to be the case (Figure S2).  
 We have also solved a heparin 8f-bound CCL3 structure at 3.1Å resolution (Table S2, 
Figure S4). The structure contains five CCL3 monomers arranged similarly to the heparin-free 
CCL3 oligomer (14) and four sugar moieties in the 8f-bound CCL3 structure (Figure 4A, S4). 
The CCL3 oligomers form a positively charged groove to bind heparin (Figure 4B). Taking 
advantage of the fact that the 45KRSR48 BBXB motif is only partially buried, K45 and R46 from 
two different BBXB motifs of CCL3 monomers form salt bridges and van der Waals contacts 
with SGN-I in heparin 8f (Figure 4C). In addition, Q19, N23, and K61 form salt bridges and 
hydrogen bonds with SGN-III and IDS-IV (Figure 4C, 4D). Furthermore, L66, D65 and Q22 
form hydrophobic interactions with heparin 8f. Interestingly, most residues involved in the 
binding of heparin to CCL3 and CCL5 oligomers are not well conserved despite the high 
conservation of residues involved in oligomerization (Figure 4E, 1E).  
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Alternative CCL3 oligomer structure: While seeking conditions to crystallize heparin-bound 
CCL3, we found a new crystallization condition that formed in the presence of 8f. We 
optimized the condition without 8f and solved an alternative CCL3 oligomer structure at 2.55Å 
resolution (Figure 5, Table S2, Figure S5A). This structure had 10 CCL3 molecules in an 
asymmetric unit, which forms a double helical rod-shaped oligomer that is similar to the 
previously reported CCL3 oligomer structure (14). However, four out of ten N-termini pass 
through the interface between CCL3 dimers and point outward towards the convex part of the 
CCL3 oligomer instead of pointing inward to the concave cavity of the CCL3 oligomer, as 
previously reported (Figure 5A) (14). While the outward pointing N-termini do not alter the 
overall structures of CCL3 monomers or dimers (except the N-termini) (Figure 5B), they push 
the CCL3 dimers apart, creating a larger gap (~3Å) between them (Figure 5C, S5B). As a 
result, salt bridges and hydrogen bonds between CCL3 dimers, including those between S33-
Y15, E30-R18, D27-R46, and Y28-R48, are broken (Figure 5C). This leads to an overall loss of 
~100Å2 of contact surface between CCL3 dimers, thus likely reducing their affinity for each 
other (Figure 5C, S5C). However, the outward pointing N-termini of CCL3 form hydrogen 
bonds between A1-S33, S2-S33 and N34-L3, which help stabilize this structure. Interestingly, 
this N-terminal protrusion profoundly increases the size of the positively charged pocket on the 
CCL3 surface, which could bind GAG (Figure 5D). This might explain why 8f facilitates the 
formation of this crystal form. However, no obvious extra density existed when CCL3 was co-
crystallized with 8f. This could be due to the low occupancy constrained by a crystal lattice 
and/or crystallization condition.  
Discussion  
 Based on our crystallographic, SAXS, and mathematical modeling analyses, we 
propose that CCL5 oligomerization follows a simple polymerization process to form rod-shaped 
double helical oligomers that are polydisperse in size (Figure 6A). Despite being very different 
in their isoelectric points and charge distribution, CCL5 has the same mechanism of 
oligomerization with CCL3 and CCL4 (14). Our CCL5 oligomer structure explains existing 
CCL5 mutational data (15, 16, 18-21, 31). Furthermore, it offers an alternative model to 
describe how CXCL4 enhances the arrest of CCL5-stimulated monocytes (40, 41). Instead of 
hetero-dimerization between CCL5 and CXCL4 shown by NMR under an acidic condition (40), 
we propose that CXCL4 can form a hetero-oligomer with CCL5 (Figure S6). CXCL4 was 
discovered based on its high affinity to heparin, and our modeling predicts that this hetero-
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oligomer would have altered electrostatic potential that could enhance GAG binding (Figure 
S6). In addition, the insertion of CXCL4 into CCL5 oligomer could also change the kinetics of 
CCL5 oligomerization. Together, they contributes to enhanced CCL5 function. This model is 
consistent with the available mutational data on the effects of 44RKNR47 and E26 mutations 
(41). It suggests an exciting hypothesis that chemokine function is regulated by hetero-
oligomerization of CC and CXC chemokines that typically form distinct dimers and higher-order 
oligomers (5).  
 Our GAG-bound CC chemokine structures reveal that a novel GAG binding site can 
form via protein oligomerization. Structures of CC chemokine oligomers reveal the molecular 
basis for how a positively charged pocket in the 50s loop of CCL5 binds GAGs even though 
the pocket formed by the BBXB motif in the 40s loop is buried. Furthermore, they show how a 
novel GAG binding site can form at the interface between CCL3 dimers. These structures offer 
a structural explanation for how multiple GAG binding sites can form upon CCL3 and CCL5 
oligomerization and strengthen the binding of these chemokines to GAG via avidity. Consistent 
with this notion, the binding affinities of chemokines are highly dependent on oligomerization 
(42).  
 Our structural studies also offer additional mechanisms for regulating the coupling of 
oligomerization and GAG binding. We found an N-terminal flipped conformation of CCL3 within 
CCL3 oligomers, which likely occurs naturally due to the flexible nature of CCL3 N-terminus. 
This conformation has a reduced dimer-dimer interface, which should destabilize it relative to 
the non-flipped conformation and thus depolymerize more readily. This conformation, however, 
has a larger positively charged pocket so it could have a higher affinity for GAGs than the non-
flipped conformation (Figure 5D). This is consistent with the fact that this crystal form is more 
readily formed when 8f was present. Thus, the presence of GAG would promote the 
dissociation of CCL3 oligomers by weakening the interaction between CCL3 dimers. This 
offers a means by which conformational switches can regulate CCL3 oligomerization and 
explains how CCL3 forms shorter oligomers in the presence of heparin (14).  
Our CCL5 oligomeric structure can, in part, explain how oligomerization affects CCL5 
functions by affecting its proteolytic sensitivity (Figure 6A) (43). Only monomeric CC 
chemokines bind and activate their respective cognate CCRs. However, they are highly 
susceptible to proteolysis, particularly at their N-termini, which is critical for receptor binding 
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and activation (44-46). In comparison, CC chemokine oligomers are resistant to proteases but 
receptor-binding incompetent since oligomerization buries CCR-binding sites. Thus, 
dimerization and oligomerization prolong the half-life of CC chemokines while reducing the 
effectiveness of these chemokines. The N-terminus of CCL5 can be cleaved by DPP IV and 
cathepsin G, thus altering the ability of CCL5 to activate its cognate receptors (43). Our CCL5 
oligomeric structure reveals that the CCL5 N-terminus is buried inside the concave surface of 
the oligomer, which should protect the oligomer from proteolytic inactivation. Oligomerization of 
CCL5 also buries substantial solvent-exposed areas. This should protect CCL5 from 
degradation by other extracellular proteases, e.g., tryptase (43). We have proposed that the 
interplay between reversible oligomerization and protease-sensitivity makes CCL3 and CCL4 
more effective chemoattractants over a longer range and thus encodes severity during 
infection or inflammation (14) (Figure 6B). This is applicable to CCL5 and other chemokine that 
can oligomerize, e.g., CCL2.  
 GAG binding in conjunction with oligomerization can profoundly affect the functions of 
CC chemokines. Similar to oligomerization, GAG binding could alter the chemotactic gradient 
of CC chemokines by modulating their sensitivity to proteases (Figure 6C). GAG could bring 
multiple CC chemokine oligomers together (Figure 6C). Consistent with this notion, analysis of 
symmetry-related molecules in our structure indicates that long chain GAGs can bring two 
CCL3 oligomers together (Figure S4B-C). GAG-mediated aggregation of CC chemokine 
oligomers could further increase the local concentration of CC chemokines to regulate the 
activation of cognate CCRs and the presentation of CC chemokines to circulating lymphocytes 
(Figure 6C). This would also promote the formation of high MW CC chemokine oligomers in 
the extracellular matrix and on cell surfaces (Figure 6C). The oligomerization of CC 
chemokines and novel GAG binding of CC chemokine oligomers could facilitate the 
aggregation of proteoglycan, e.g., CD44, which in turn promotes non-CCR mediated signaling, 
e.g., tyrosine phosphorylation (Figure 6C). Given the complexity of how chemokines recruit 
immune cells, which involves cell arrest and adhesion onto the endothelial cells, extravasation 
across blood vessels, and cell migration toward the source of the CC chemokines, future 
investigation will be required to elucidate how the GAG binding and oligomerization of CC 
chemokines are coupled to affect each step of chemokine-mediated cell recruitment under 
normal physiological and pathological settings.  
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Methods 
Chemokine expression and purification, crystallization, data collection, and structure 
determination: The expression of thioreduxin-tagged CCL5, CCL5(4-68), and CCL3 in E. coli, 
the removal of thioreduxin-tag by enterokinase or TEV protease, and the purification of these 
chemokines by Ni-NTA, source-Q, and heparin columns are done similar to methods described 
previously (14, 47). The octasaccharide heparin, MLZ-8f was synthesized as described (35). 
Crystals of CC chemokines in the presence and absence of heparin 8f were grown using 
hanging drop vapor diffusion and cryo-protected under the conditions listed in Table S2. 
Diffraction data were collected at 100 K at beamline 19-ID or 19-BM at Advanced Photon 
Source, Argonne National Laboratory and processed with HKL3000 (48). Molecular 
replacement was done using PHASER (49) and structural refinement and rebuilding were 
performed with COOT (50) and PHENIX (51-53). Further details are provided in supplemental 
methods. 
SAXS Data Acquisition and Analysis - SAXS data were collected at the BioCAT/18ID 
beamline at Advanced Photon Source, Argonne National Laboratory. Chemokine (0.6 mg/ml 
CCL5, 0.9 mg/ml CCL5(4-68), and 1 mg/ml CCL3) in the presence or absence of 1-10 μg/ml 
heparin (Alfa Aesar) in the buffer containing 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1mM 
EDTA and 1mM β-mercaptoethanol was used for data collection. ATSAS package, Primus, 
and Crysol were used for data reduction and analysis (53, 54). A simple scheme for 
polymerization assuming equal probability of binding or unbinding between dimers 
independent of location was used to generate a model of oligomer size distribution to fit the 
SAXS data (14, 37). Further details are provided in supplemental methods. 
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Figure Legends 
Figure 1 Structure of CCL5(4-68) oligomer. A) Ribbon representation of CCL5(4-68) hexamer 
(PDB=5CMD). B) Detailed interactions between CCL5 dimers. C) Charge complementarity 
between CCL5 dimers and CCL3 dimers. The dimer interface is colored from negative surface 
(red, -1kT) to positive (blue +1kT). D) Comparison of CCL5 and CCL3 20mer. The PDB code 
of CCL3 oligomer is 2X69. Electrostatic surface is colored as calculated by APBS (< -1kT in 
red and > +1kT in blue). The 20mer models of CCL5 and CCL3 are built by the offset 
alignment and the use of symmetry related structure, respectively. E) Sequence alignment of 
CCL5 and CCL3. Identical and conserved residues are in red and boldface, respectively. Blue 
and cyan arrows indicate residues that form hydrophilic and hydrophobic interactions between 
CCL dimers, respectively. 
Figure 2 SAXS scattering curve with cross-section, Guinier rod plot in inset (left) and the pair 
distribution (right) of CCL5 (A) and CCL3 (B). CCL5 data is fit with the fixed length oligomers of 
three CCL5 structure models, 5CMD-26mer (26mer of CCL5 structure with pdb code=5CMD), 
2L9H-14mer, and 2VXW-28mer, which structures are shown as ribbon representation at the 
bottom of panel A. The length is chosen based on the optimal fitting χ values of 1.16, 1.91, and 
2.03 for CCL5 5CMD-26mer, 2L9H-14mer, and 2VXW-28mer, respectively where χ was 
calculated by χ2 =(1/(N-1))×Σj((μI(sj)–Iexp(sj))/σ(sj))2 (N is the number of experimental points and 
μ is the scaling factor). Data is also fit with the mathematical model for the formation of double 
helical oligomers that are polydisperse in size (Polydisperse) using the equation for the 
concentration of oligomers of k monomers is ẚ(ⱴ) =  ௖Ԉῼ (1 − ߙ
ῼ)ߙቀ
Ӷ
మିῺቁ, where α, the only fitting 
parameter, is directly related to the dissociation constant between dimers and ct is the total 
protein concentration. The same process is used to analyze CCL3 SAXS data with either 
CCL3 10mer structure (pdb=2X69) (2X69-10mer) or a simple polymerization model that lead to 
the formation of CCL3 oligomers polydiperse in size (Polydiperse).  
Figure 3 Structure of heparin 8f-bound CCL5 hexamer. (A) Overall structure of 8f-bound CCL5 
oligomer. CCL5 is shown in ribbon representation and colored by chain. Carbon (yellow), 
oxygen (red), nitrogen (blue) and sulfur (orange) of heparin are depicted in stick. (B) 
Electrostatic potential is colored from red (-10kT) to blue (+10kT). (C) Close-up view and (D) 
schematic representation of the interaction of CCL5 and heparin 8f. Red “eyelashes” indicate 
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hydrophobic interactions. (E) Ribbon representation of heparin disaccharide I-S bound CCL5 
dimer (PDB=1U4L).  
Figure 4 Structure of heparin 8f-bound CCL3. A) Overall structure of 8f-bound CCL3. CCL3 is 
shown in ribbon representation and colored by chain. Carbon (yellow), oxygen (red), nitrogen 
(blue) and sulfur (orange) of heparin are depicted in stick. B) Electrostatic potential is colored 
from red (-1kT) to blue (+1kT). (C) Close-up view and (D) schematic representation of the 
interaction of CCL3 and heparin 8f. Red “eyelashes” indicate hydrophobic interactions. E) 
Sequence alignment of CCL5 and CCL3. Identical and conserved residues are in red and 
boldface, respectively. Cyan arrows indicate residues involved in the interaction of heparin with 
CCL3 while blue arrows indicate those with CCL5. 
Figure 5 Structure of alternative CCL3 oligomer. (A) Ribbon representation of CCL3 decamer 
with four N-termini pointing outward and the comparison with CCL3 decamer with all N-termini 
pointing inward. (B) Alignment of monomer and dimer between CCL3 pointing outward and 
that pointing inward. Molecule is colored by RMSD. (C) Alignment of CCL3 with N termini 
pointing outward (colored, PDB=5COR) and that with N-termini inward (grey, PDB=2X69). 
Chain F was used for alignment. Chain F and Chain G have outward N-terminal. The close-up 
view shows gained hydrogen bonds (right, top) or lost hydrogen bonds (right, bottom) for CCL3 
with N-termini pointing outward. D) Electrostatic surface potential of CCL3 decamer with N-
termini pointing outward (top) and that with all N-termini pointing inward. The decamer surface 
is colored from negative (red -1kT) to positive (blue +1kT).  
Figure 6 Roles of oligomerization, GAG binding, and proteolytic degradation of CC 
chemokines. (A) Equilibrium of CC chemokine oligomeric states and their properties in 
receptor binding and protease sensitivity. (B) Distribution of monomeric CC chemokine (log 
scale) from the source over the distance (linear scale). At low and medium levels of CC 
chemokine where it is most monomer or a mixture of monomer and dimer, respectively, cells 
will be directed to the center of CC chemokine source. However, at high CC chemokine level 
where it also forms oligomer, cells will only be migrated to the peripheral of CC chemokine 
source, rather than to the center. This would help to prevent the spread of invading pathogens 
in a severe infection. This is because the difference in CC chemokine monomer level within the 
cell length is less than required difference for the effective chemotaxis. (C) Effects of GAG 
binding and oligomerization to the functions of CC chemokines (see discussion).  
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